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Abstract
Background: The targeted delivery of cancer therapeutics represents an ongoing challenge in the field of drug
development. TRAIL is a promising cancer drug but its activity profile could benefit from a cancer-selective delivery
mechanism, which would reduce potential side effects and increase treatment efficiencies. We recently developed the
novel TRAIL-based drug platform TR3, a genetically fused trimer with the capacity for further molecular modifications
such as the addition of tumor-directed targeting moieties. MUC16 (CA125) is a well characterized biomarker in several
human malignancies including ovarian, pancreatic and breast cancer. Mesothelin is known to interact with MUC16 with
high affinity. In order to deliver TR3 selectively to MUC16-expressing cancers, we investigated the possibility of targeted
TR3 delivery employing the high affinity mesothelin/MUC16 ligand/receptor interaction.
Methods: Using genetic engineering, we designed the novel cancer drug Meso-TR3, a fusion protein between native
mesothelin and TR3. The recombinant proteins were produced with mammalian HEK293T cells. Meso-TR3 was
characterized for binding selectivity and killing efficacy against MUC16-positive cancer cells and controls that lack
MUC16 expression. Drug efficacy experiments were performed in vitro and in vivo employing an intraperitoneal
xenograft mouse model of ovarian cancer.
Results: Similar to soluble mesothelin itself, the strong MUC16 binding property was retained in the Meso-TR3 fusion
protein. The high affinity ligand/receptor interaction was associated with a selective accumulation of the cancer drug
on MUC16-expressing cancer targets and directly correlated with increased killing activity in vitro and in a xenograft
mouse model of ovarian cancer. The relevance of the mesothelin/MUC16 interaction for attaching Meso-TR3 to the
cancer cells was verified by competitive blocking experiments using soluble mesothelin. Mechanistic studies using
soluble DR5-Fc and caspase blocking assays confirmed engagement of the extrinsic death receptor pathway.
Compared to non-targeted TR3, Meso-TR3 displayed a much reduced killing potency on cells that lack MUC16.
Conclusions: Soluble Meso-TR3 targets the cancer biomarker MUC16 in vitro and in vivo. Following attachment to the
tumor via surface bound MUC16, Meso-TR3 acquires full activation with superior killing profiles compared to
non-targeted TR3, while its bioactivity is substantially reduced on cells that lack the tumor marker. This prodrug
phenomenon represents a highly desirable property because it has the potential to enhance cancer killing with fewer
side-effects than non-targeted TRAIL-based therapeutics. Thus, further exploration of this novel fusion protein is
warranted as a possible therapeutic for patients with MUC16-positive malignancies.
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Background
TRAIL (TNF-related apoptosis-inducing ligand) is a
member of the TNF (Tumor Necrosis Factor) superfamily
and induces apoptosis upon binding to its death receptors
DR4 and DR5 [1-3]. Two unique properties have been
described for TRAIL that renders this cytokine highly
attractive for cancer therapy. First, it selectively acts on
malignant/transformed cells despite the fact that many
normal host cells also express the activating death recep-
tors [4,5]. This cancer selective advantage can be lost
under inflammatory conditions. For example, hepatocytes
under the influence of chemotherapy can become sus-
ceptible to TRAIL due to upregulation of activating death
receptors [6-8]. Secondly, TRAIL induces the death re-
ceptor pathway independent of p53, a tumor suppressor
which plays an important role in tumor formation and
progression [9].
To further optimize the treatment efficiency of TRAIL-
based cancer drugs, targeting concepts have been eva-
luated which serve two main purposes: 1) to accumulate
the drugs at the tumor site and thereby limiting sequestra-
tion by non-transformed host cells (reduced side-effects)
and 2) to immobilize TRAIL to the cancer cell membrane
which converts a soluble drug into a membrane-bound
analog. This conversion results in enhanced death re-
ceptor signaling and cell death induction [10]. Various ap-
proaches have been described for targeting death receptor
ligands to the tumors including construction of TRAIL
fusion proteins using antibody fragments directed against
overexpressed tumor antigens [11].
We recently described a method of producing soluble
TRAIL from mammalian cells by genetic fusion [12]. This
novel human TRAIL trimer, designated TR3, is comprised
of three consecutive extracellular TRAIL domains fused
together in a head-to-tail configuration. It is devoid of
artificial linker sequences and is therefore “all-human”.
The killing activity of TR3 is comparable to that of com-
mercially available recombinant TRAIL (rTRAIL). TR3
is more stable at physiologic temperatures and has a
superior pharmacologic profile. Furthermore, genetic
modification of the TR3 drug platform is feasible allo-
wing delivery of preassembled bioactive TRAIL trimers
to selected cell surface markers in a stoichiometrically-
controlled fashion [12].
In our current study, we sought to deliver TR3
selectively to the cancer cells employing a native, high-
affinity ligand/receptor interaction between mesothelin
and MUC16, also known as CA125 [13]. MUC16 is an
established biomarker in ovarian cancer that is also over-
expressed in other malignancies such as pancreatic [14,15]
and breast cancers [16]. We thus generated a mesothelin-
TR3 fusion protein, designated Meso-TR3, and performed
biochemical and functional characterization experiments
in vitro and in vivo. One of the key characteristics of this
novel cancer drug is its potency on MUC16-positive
cancer cells with reduced killing abilities on MUC16-
negative cancer cells. This “prodrug” phenomenon is
highly desirable as it is predicted to substantially reduce




All cell lines used in the experiments were obtained from
the American Type Culture Collection (ATCC, Manassas,
VA). Recombinant human TRAIL was purchased from
Enzo Life Sciences (formerly BIOMOL, International,
Farmingdale, NY). Mouse anti-mesothelin mAb (clone K1)
was purchased from Santa Cruz Biotech (Santa Cruz, CA).
Construction of plasmids and protein production
Soluble mesothelin was generated by inserting a FLAG
tagged, GPI anchor-deleted mature form of a mesothe-
lin cDNA into the expression plasmid sT-DAF [17] that
contains a signal peptide to ensure protein secretion
from mammalian cells. The FLAG tag was inserted to
distinguish genetically engineered mesothelin from the
endogenously expressed mesothelin on ovarian cancer
cells. The basic TR3 expression plasmid was described
previously [12], modified to include an internal 6 × His
tag. Meso-TR3 was generated by N-terminal insertion
of soluble mesothelin into the TR3 drug platform. The
recombinant TR3 forms, soluble mesothelin, and DR5-Fc
were produced by transient expression in HEK293T
cells using Gibco Opti-Mem serum free medium and
TransIT-293 transfection reagent (MIR2700, MIRUS Bio
LLC, Madison, WI), as per the manufacturer’s instruc-
tions. To obtain concentrated protein stocks, the super-
natants were applied to centrifugal filter devices with a
10 kDa molecular cut-off (Centricon Plus-20, Millipore,
Billerica, MA). DR5-Fc was purified using Protein A
columns as per the manufacturer’s instructions (Pierce,
Rockford, IL).
Flow cytometry
To assess the MUC16 surface expression, cells were incu-
bated with anti-MUC16 mAb X75 (Abcam, Cambridge,
MA) followed by staining with FITC conjugated secon-
dary antibody (anti-mouse IgG, Sigma-Aldrich, St. Louis,
MO). For binding studies of Meso-TR3 to OVCAR3 cells,
Meso-TR3 was first preincubated with DR5-Fc. Under
constant agitation, OVCAR3 cells were then combined
with the Meso-TR3/DR5-Fc complexes for one hour,
washed and subsequently incubated with anti-FLAG
mAb M2 (Sigma-Aldrich, St. Louis, MO), followed
by FITC conjugated secondary Ab (anti-mouse IgG,
Sigma-Aldrich) and analyzed employing flow cytometry
(FACSCalibur, BD Biosciences, San Jose, CA).
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Confocal microscopy
OVCAR3 and HeLa cells were cultured for 24 h on
millicell EZ slides (Millipore) and then fixed with 4%
paraformaldehyde. The cells were blocked with serum-
free Protein Block (Dako, Carpinteria, CA). Primary
antibodies for FLAG (mouse mAb M2) and MUC16
(rabbit pAb, Sigma-Aldrich) were allowed to bind for
2 h, washed and detected with the respective secondary
Abs Alexa Fluor 488 goat anti-mouse IgG (Invitrogen,
Carlsbad, CA) and Alexa Fluor 555 goat anti-rabbit IgG
(Invitrogen). Confocal images were taken on a Zeiss
LSM 510 META Confocal Laser Scanning Microscope
(Zeiss, Jena, Germany).
Analysis of cell death
OVCAR3, HeLa, and Jurkat cells were seeded in 96 well
plates. Unless otherwise stated, the cells were treated the
following day and assayed 18 hours later using CellTiter-
Glo Luminiscent Viability Assay (Promega, Madison,
WI). Data were recorded with a SpectraMax Gemini mi-
croplate spectrofluorometer, Molecular Devices (Silicon
Valley, CA).
Immunoblotting
Transfection supernatants were submitted to 10% SDS-
PAGE and transferred onto a nitrocellulose membrane.
After blocking with dry milk, the membranes were
incubated with a rabbit primary antibody (anti-human
TRAIL pAb, Peprotech, Rocky Hill, NJ) followed by an
HRP-conjugated secondary antibody (goat anti-rabbit
IgG, Santa Cruz Biotech) and developed with Immunstar
Western C kit (Bio-Rad, Hercules, CA) using the Chemidoc
XRS plus Imaging system (Bio-Rad).
Animals
Eight week old female Nonobese Diabetic/Severe Combined
Immunodeficiency mice (NOD/SCID; Harlan, IN) were
used as hosts for tumor xenografts. Human OVCAR3
tumor cells (2 × 106 cells per animal), stably expressing
the eYFP-Luciferase fusion protein were injected into the
abdomen (i.p.) prior to drug treatments (300 μL/mouse/
day). Procedures involving mice were approved by the
Washington University Animal Studies Committee and
conducted in accordance with the guidelines for the care
and use of laboratory research animals established by the
NIH.
Bioluminescence imaging
For bioluminescence imaging of living animals, mice
were injected intraperitoneally with 150 μg/g D-luciferin
(Biosynth, Naperville, IL) in PBS, anesthetized with 2.5%
isoflurane, and imaged with a charge-coupled device
(CCD) camera-based bioluminescence imaging system
(IVIS 100; Caliper, Hopkinton, MA) with exposure times
ranging from 1 to 60 seconds as described elsewhere
[18]. The signals were displayed as photons/sec/cm2/sr.
Statistical analyses
Treatment efficiency of in vitro killing assays are presented
as means ± SEM. Treatment efficiency in vivo is expressed
as reduction in bioluminescence signal relative to the indi-
vidual animal’s baseline intensity as means ± SEM. Statis-
tical significance is defined as P < 0.05 and was calculated
employing analysis of variance (one-way ANOVA,
Tukey’s Multiple Comparison Test) and the Student’s
t-test (unpaired) as indicated using GraphPad Prism
(V 4.02) software.
Results
Design, generation and biochemical characterization of
Meso-TR3
Soluble mesothelin has been shown to bind to MUC16
rapidly and with high affinity [13]. Since endogenous
mesothelin is attached to the cell surface via a GPI anchor
[19,20], we designed a secreted form of the glycoprotein
by deleting its GPI signal sequence (Figure 1A, Meso). For
immunologic detection purposes, we included a FLAG
epitope tag, located at the amino-terminus of the secreted
protein (not shown). The recombinant protein was pro-
duced in HEK293T cells and Western blot analysis con-
firmed its identity with a molecular weight of ≈ 40 kDa
(not shown). To convert TR3 (Figure 1A, center) into a
MUC16-targeted cancer drug, we inserted the entire
cDNA of soluble mesothelin (including the N-terminal
FLAG tag) to the 5′-terminus of a TR3 expression plasmid
(Figure 1A, Meso-TR3). The resulting genetic constructs
were expressed in mammalian 293T cells and characte-
rized by Western blot analysis. Meso-TR3 was identified
as a fusion protein with an apparent molecular weight
of ≈ 100 kDa, with the parental molecule TR3 being ≈
60 kDa (Figure 1B), consistent with a size reduction of
40 kDa, the molecular weight of the mature form of
soluble human mesothelin. Using this method of mo-
lecular weight detection, we were unable to identify
fragmentation products, suggesting lack of proteolytic
degradation of Meso-TR3.
Meso-TR3 binds to MUC16 on the cancer cell membrane
As our primary model system for binding and functional
killing experiments, we chose the well-characterized
ovarian cancer cell line OVCAR3. These cells have been
described to express MUC16 on their plasma membrane
[21]. In addition, they are moderately sensitive to recom-
binant TRAIL [22-24]. In order to confirm the MUC16
expression profile on OVCAR3 cells, we performed flow
cytometry and were able to detect a strong surface ex-
pression with a homogenous staining pattern for 100%
of the cells (Figure 2A). We then tested the ability of
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soluble, FLAG-tagged recombinant mesothelin to bind
to native, membrane-bound MUC16 employing an
in vitro binding assay using OVCAR3 cells. We could
indeed confirm that soluble mesothelin was capable of
binding to OVCAR3 cells by flow cytometry (Figure 2B).
The staining pattern correlated well with the MUC16
expression profile of this cell line as nearly 100% of the
cells were positive for the FLAG epitope tag, i.e. bound
recombinant mesothelin. This pilot experiment was
crucial as it confirmed not only the binding capacity of
recombinant mesothelin to native MUC16 but also de-
monstrated accessibility of the epitope tag in the context
of the mesothelin/MUC16 interaction. To demonstrate
broader applicability of our targeting concept, a similar
study was also performed with the cervical cancer cell
line HeLa (see below).
It was predicted that the multi-domain Meso-TR3
fusion protein would bind to OVCAR3 cells via two
discrete mechanisms: 1) via the mesothelin/MUC16 inter-
action and 2) via the TR3/death receptor interaction (both
DR4 and DR5 are expressed in OVCAR3 cells, data not
shown and [24]). Since these circumstances would have
complicated the interpretation of binding studies me-
diated exclusively via the mesothelin moiety of Meso-TR3,
we first saturated the death receptor binding sites of
Meso-TR3 with soluble death receptor 5 (DR5-Fc). In a
following step, the Meso-TR3/DR5-Fc complexes were
added to OVCAR3 cells in suspension. After several wa-
shing steps, the cells were stained for the presence of the
FLAG epitope tag as evidence for drug binding to the
OVCAR3 reporter cells. Using flow cytometry, we de-
tected a strong and homogeneous fluorescence signal for
cell-bound Meso-TR3, which was nearly identical to the
MUC16 staining profile and similar to the binding pattern
of soluble mesothelin alone (Figure 2C). Further evidence
that Meso-TR3 and MUC16 co-localize on the plasma
membrane of the target cells was obtained by employing
confocal microscopy. Using the same detection system
(anti-FLAG antibody) and death receptor blocking strat-
egy (DR5-Fc pretreatment), we detected strong fluo-
rescence signals for both the MUC16 eptiope (red) and the
FLAG tag of Meso-TR3 (green) (Figure 2D), with no
“cross-bleeding” between the detection channels (not
shown). Importantly, the two signals overlapped (Figure 2D,
“merge”) and suggest that Meso-TR3 co-localizes with the
mesothelin receptor MUC16 on the same cancer cell
membrane.
The mesothelin/MUC16 interaction converts Meso-TR3
into a potent cancer drug
In order to compare the relative ability of cell death in-
duction between Meso-TR3 and non-targeted TR3, it
was important to establish the killing capacity of each
drug mediated exclusively by the TR3 effector domain.
Thus, we selected the TRAIL-sensitive leukemia cell line
Jurkat which lacks expression of MUC16 (not shown).
Under the assumption that the mesothelin epitope of
Meso-TR3 would not impact the killing capacity of the
MUC16-targeted TRAIL fusion protein, we established
the killing curves for TR3, Meso-TR3 and recombinant
TRAIL (rTRAIL) and identified conditions under which
all TRAIL drugs induced cell death to the same degree
in the absence of the tumor marker MUC16 (Figure 3A).
This killing profile changed significantly when the same
conditions were used to treat MUC16-positive OVCAR3
cells, known to be sensitive to recombinant TRAIL
[22-24]. Non-targeted TR3 turned out to be quite ineffi-
cient with only ≈ 10% cell killing capacity at the highest
dose used (Figure 3B). Importantly, TR3’s killing profile
was identical to that of rTRAIL, which is consistent with
Figure 1 Design and biochemical characterization of the
MUC16-targeted TRAIL trimer TR3. A, Schematic representation of
the proteins used in this study. Soluble mesothelin (Meso) containing
an N-terminal FLAG tag (not shown), the parental TRAIL drug platform
TR3 (center) and the MUC16-targeted mesothelin-TR3 fusion protein
(Meso-TR3) were produced by transient transfection of HEK293T cells.
N, amino-terminus; C, carboxyl-terminus. B, Western blot analysis
(reducing conditions) documents the molecular weights of TR3
(≈60 kDa, lane 2) and Meso-TR3 (≈100 kDa, lane 3) using anti-TRAIL
pAb. Supernatant from mock-transfected HEK293T cells served as a
negative control (lane 1).
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our earlier findings in that both drugs activated the ex-
trinsic death pathway equally well and suggested that
each trimer assumes the same native conformation [12].
Treatment with Meso-TR3, however, resulted in an en-
hanced killing profile approaching 65% cell death at the
highest drug dose employed in this experiment (Figure 3B).
Figure 2 Meso-TR3 binding to MUC16-expressing cancer targets. A, FACS-analysis of OVCAR3 cells assessed for expression of MUC16 (mAb X75)
and a PE-conjugated secondary Ab (red line). The secondary Ab alone served to establish the background fluorescence (black line). B, OVCAR3 cells in
suspension were incubated with HEK293T-derived culture supernatant containing soluble mesothelin. Mesothelin binding was detected via anti-FLAG
antibody staining (mAb M2) and a FITC-conjugated secondary Ab (green line). Cells treated with culture medium alone served as negative control (black
line). C, OVCAR3 cells in suspension were incubated with HEK293T-derived culture supernatant containing Meso-TR3. To prevent binding of Meso-TR3
via TR3/death receptor interaction, Meso-TR3 was complexed with soluble DR5-Fc. Meso-TR3 binding was detected via anti-FLAG antibody staining
similar to (B) using mAb M2, followed by FITC-conjugated secondary Ab (green line). Cells treated with culture medium alone served as negative control
(black line). D, OVCAR3 cells were grown on 4-chamber slides and incubated the following day with Meso-TR3 complexed with DR5-Fc, similar to what
has been described for (C). After washing, the cells were stained with a mixture of MUC16 pAb (red) and FLAG mAb (green), respectively. The cells were
counterstained with TOPRO3 (blue, nuclei) and analyzed by confocal microscopy. The individual channels were overlaid to document co-localization of
tumor marker and the targeted cancer drug (Merge). Original magnification: 63 × .
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Linear regression analysis of the killing curves suggested a
7 to 12-fold stronger activity profile of Meso-TR3 when
compared to TR3 and rTRAIL in OVCAR3 cells.
In order to obtain quantitative drug concentration data,
we employed semi-quantitative Western blot an analysis.
This detection method was selected as it does not rely on
native protein conformations such as ELISA assays,
especially because we began to suspect that the meso-
thelin domain of our Meso-TR3 fusion protein might have
conformational properties which would interfere with the
more commonly used ELISA-based assays. When drug
concentrations which had achieved identical killing ca-
pacities on MUC16-negative Jurkat cells were compared,
we consistently found ≈ 6 to 8-fold stronger signal inten-
sities for Meso-TR3 compared to TR3 (Additional file 1:
Figure S1). To address this difference in drug concentration,
we increased the TR3 dose to that of Meso-TR3 and re-
peated the killing experiments with Jurkat and OVCAR3
cells. TR3 was now capable of killing more Jurkat cells
than Meso-TR3 under these conditions (Additional file 2:
Figure S2A). However, TR3’s impact on killing OVCAR3
cells did not improve, while Meso-TR3 was still more
potent in killing MUC16 expressing OVCAR3 cells
(Additional file 2: Figure S2B). Overall, these data show
that a significantly higher concentration of Meso-TR3 is
required to achieve equivalent biological effects on
MUC16-deficient cells and, at equipotent doses, Meso-
TR3 is substantially more effective than TR3 on MUC16-
positive cancer cells.
In a next step, the killing activity of Meso-TR3 on
MUC16-positive cancer cells was assessed in a precli-








Figure 3 Meso-TR3 is a targeted therapeutic on MUC16-expressing tumor cells. A, The cell killing profiles of TR3, Meso-TR3 and rTRAIL [0.2
ng/μL] were established on the MUC16-deficient T cell leukemia cell line Jurkat. NS, not significant (one-way ANOVA). B, The same killing assay as in (A)
using identical drug concentrations but the MUC16-positive ovarian cancer cell line OVCAR3 instead. *, P < 0.0075; NS, not significant (one-way ANOVA).
C, NOD/SCID mice were injected i.p. with 2 × 106 luciferase labeled OVCAR3 cells. The following day the baseline signal intensity was determined by live
animal imaging. Three groups of mice (n = 7) were treated i.p. for 7 days with 300 μL medium alone (ctrl.), TR3 and Meso-TR3. Treatment efficiency is
plotted as fold change (mean ± SEM) of signal intensity relative to the baseline signal obtained prior to treatment (negative data reflect a reduction in
tumor burden). *, P< 0.016; NS, not significant (one-way ANOVA).
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OVCAR3 cells were injected via the intraperitoneal route
into NOD/SCID mice. Luciferase activity was determined
via non-invasive bioluminescence imaging [18]. The mice
were treated via i.p. injections with medium only (control),
or equipotent doses of either non-targeted TR3 or Meso-
TR3 for 7 days (compare Figure 3A). The abdominal
tumor burden (signal intensity) was then recorded at
selected time points. The mice treated with Meso-TR3
responded with a robust decline in tumor burden by
nearly a 600-fold reduction of the luciferase signal at
7 days post-treatment, while the control group and the
mice treated with TR3 alone did not respond to the treat-
ment (Figure 3C). These results suggest that native
MUC16 is also available in vivo to anchor Meso-TR3 to
the tumor cell membrane and that this tumor homing
capacity directly corresponds with an enhanced target cell
killing mechanism, in agreement with our in vitro killing
data.
The enhanced Meso-TR3-mediated cell death is due to its
conversion into a membrane anchored TRAIL drug
Based on the much enhanced killing profile of Meso-TR3
on MUC16-positive OVCAR3 cells, we hypothesized that
the mesothelin/MUC16 interaction, i.e. the surface tethe-
ring of Meso-TR3 was responsible for the observed effects.
To investigate this assumption, we performed a killing
assay in the presence of increasing concentrations of
soluble mesothelin to block the MUC16/Meso-TR3
interaction. As predicted, we were able to achieve a dose-
dependent reduction in cell killing from 80% (no competi-
tor) to 40% (highest competitor dose) (Figure 4A). We did
not expect complete protection from apoptosis of cells
Figure 4 Phenotypic characterization of MUC16-targeted Meso-TR3. A, OVCAR3 cells were challenged with a constant amount of Meso-TR3
(80% specific cell death) and increasing concentrations of soluble mesothelin to study the impact of the mesothelin/MUC16 interaction of Meso-TR3.
B, OVCAR3 cells were challenged with a constant amount of Meso-TR3 (90% specific cell death) and increasing concentrations of DR5-Fc to verify
involvement of the extrinsic death pathway as a mechanism of Meso-TR3 killing. C, OVCAR3 cells were treated with a constant amount of Meso-TR3
(75% specific cell death) in the presence of Z-VAD-FMK, a pan-caspase inhibitor, vital mediators of apoptosis. Cells treated with DMSO were used as a
control. P < 0.001 (one-way ANOVA). D, MUC16-deficient Jurkat cells were treated with low dose Meso-TR3 (33% specific cell death) in the presence of
anti-mesothelin mAb. Cells treated with anti-mesothelin Ab alone served as a control. P < 0.0019 (Student’s t-test). Error bars, mean ± SD. Results are
representatives of at least 2 independent experiments done in triplicates.
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treated with Meso-TR3, even assuming 100% MUC16
blockade with soluble mesothelin, since all TRAIL variants
(including TR3, recombinant rTRAIL and Meso-TR3)
exhibit baseline apoptosis-inducing activities in MUC16-
deficent cancer cells due to direct interaction of the
TRAIL timer with cell surface DR4/5.
In order to rule out phenotypic alterations that the
addition of the MUC16 targeting moiety mesothelin to
the TR3 drug platform might have caused, we asked if the
induction of cell death was exclusively mediated via the
extrinsic death receptor pathway. Two lines of evidence
suggest that this mechanism is well preserved following
Meso-TR3 treatment. First, when soluble DR5-Fc was
added to a standard killing assay using MUC16-positive
OVCAR3 cells, Meso-TR3’s killing capacity was nearly
completely blunted, evidenced by a gradual decrease in
cell death from 90% in the absence of the soluble receptor
to below 10% at the highest DR5-Fc concentration
(Figure 4B). Further evidence for the involvement of
the death receptor signaling cascade induced by Meso-
TR3 was obtained employing the pan-caspase inhibitor
Z-VAD-FMK, which blocks intracellular caspases acti-
vated via the extrinsic death pathway of apoptosis.
Z-VAD-FMK turned out to protect the cells completely
from Meso-TR3-induced cell death (Figure 4C).
Higher order TRAIL aggregates have been associated
with increased activity due to more efficient death recep-
tor clustering. This clustering, especially regarding the
DR5 receptor, is not exclusively cancer cell selective and
is generally considered undesired due to unintentional
side effects exerted on normal host cells also capable of
expressing DR4 and/or DR5 [25]. In an attempt to test if
Meso-TR3 forms higher order aggregates in solution, we
treated Jurkat cells with Meso-TR3 in the presence of a
monoclonal antibody (K1), directed against the meso-
thelin moiety of the fusion protein. Using a sublethal
dose of Meso-TR3 (33% cell death), we were able to
demonstrate a dose-dependent augmentation of cell
death to nearly 100% at the highest concentration of
cross-linking mesothelin antibody (Figure 4D). These
results strongly suggest that Meso-TR3 does indeed
assume a monomeric configuration in solution that can
be functionally enhanced by forming higher order aggre-
gates (Meso-TR3 dimers). In contrast to earlier toxicity
concerns of utilizing aggregated TRAIL preparations for
clinical applications, Meso-TR3 would only form higher
order clusters at the tumor cell membrane following
interaction with multiple binding sites on MUC16,
which then converts the soluble drug into a highly
potent membrane anchored tumor cell killer.
Meso-TR3 kills in a MUC16-selective manner
In order to study target selectivity aspects of Meso-TR3
toward MUC16-expressing cancers, we took advantage
of the fact that the cervical cancer cell line HeLa is com-
prised of a native mix of MUC16-positive and negative
cells (80% and 20%, respectively). We therefore per-
formed confocal microscopy on HeLa cells to study the
surface tethering of Meso-TR3 using the same con-
ditions described above for drug binding to OVCAR3
cells (Figure 2D). We found that cells positive for the
MUC16 tumor marker were heavily coated with Meso-
TR3 (Figure 5A), while cells with nearly undetectable anti-
gen expression were incapable of capturing Meso-TR3
and stained only weakly for the targeted drug (Figure 5A,
arrow). Based on these findings, we anticipated that
Meso-TR3 would have a higher affinity for the MUC16-
positive population and selectively eliminate these from
the HeLa cell pool. Under conditions where both drugs
killed the same number of MUC16-negative Jurkat
cells, HeLa cells were more susceptible to Meso-TR3
(Additional file 3: Figure S3), similar to what we have
shown for OVCAR3 cells. In addition to its much en-
hanced killing profile on HeLa cells, Meso-TR3 treatment
resulted in a more than 30% reduction of the MUC16-
positive cell population from 80% to 54% (Figure 5B). In
contrast, non-targeted TR3 was incapable of shifting the
MUC16 ratio in this cervical cancer cell line due to its
non-targeted nature. Along these lines, and to further
underscore the universal applicability of our targeted
drug delivery concept, similar results were obtained with
BxPC3 pancreatic cancer cells in vitro (data not shown).
Discussion
If we were to seek an ideal cancer therapeutic, we would
design a drug that could be delivered systemically, seek
out its target autonomously, ignore all non-targets and,
upon arrival at its destination, would fully unleash its
intended pharmacologic activity. Such a selective activity
profile might be most beneficial for the treatment of hu-
man malignancies wherein treatment with conventional
chemotherapy is known to be associated with debili-
tating side effects directly linked to an adverse impact
on the quality of life of the patients.
Nearly 20 years ago, the TNF superfamily member
TRAIL was identified and it immediately became ap-
parent that it exhibited many properties of an ideal can-
cer therapeutic because of its strong apoptosis induction
on transformed cancer cells and lack of harmful side
effects for the host. Since then, TRAIL has been eva-
luated in a number of clinical trials and found to be
effective against several types of cancers [26]. In order to
make improvements in the field of TRAIL-based drug
development, investigators have looked for ways to sta-
bilize the bioactive trimer by several means, including
incorporation of trimerization domains or by simply
adding Zn2+ to the production process which aids the
coordination of the three cysteines present once in each
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TRAIL domain [27]. The next step toward more versa-
tile TRAIL drugs was achieved by incorporating target-
ing moieties directed against cancer-specific surface
markers. Cancer targeting was primarily achieved using
antibody fragments (scFv) on the basis of the con-
ventional monomeric TRAIL cDNA [11,28]. This tech-
nology turned out to be quite effective, despite a 1:1
stoichiometry of the targeting and effector domain of
the fusion proteins which could potentially interfere with
the formation of bioactive TRAIL trimers. In fact, we
have produced scFv-TRAIL fusion proteins in mam-
malian cells employing two different antibody fragments
with one drug being constitutively active (regardless of
the presence of a secondary cancer antigen), while the
other drug was only active in the presence of the target
antigen (D. Spitzer, unpublished data). These results
underscore the unpredictability of drug properties that
could result from exchanging targeting moieties (scFv)
generally accepted to have nearly identical three dimen-
sional structures.
We have recently designed a new method to produce
bioactive soluble TRAIL from mammalian cells, desig-
nated TR3, not feasible when attempted in the context
of a monomeric expression format [29]. In addition to
its much enhanced stability compared to certain recom-
binant TRAIL preparations [12], this genetically fused
TRAIL trimer has the capacity to serve as a drug plat-
form for the design of targeted cancer therapy under
stoichiometric control. For example, fusing a scFv to the
N-terminus of TR3 resulted in a RBC-targeted scFv-TR3
fusion protein with a favorable 1:3 stoichiometry that
was capable of tethering human TR3 to mouse RBCs
which were thereby converted into potent effector sur-
faces in analogy to nanoparticles, capable of facilitating
robust bystander (trans) cell killing [12]. In our current
study, we characterized a tumor-targeted variant of TR3
by harnessing the strong binding affinity of the two well
described biomarkers mesothelin and MUC16. MUC16
is not only an established biomarker in ovarian cancer, it
has also been explored as a promising target for cancer
therapy. In a recently reported phase I clinical trial of
DMU-C5754A (an anti-MUC16 antibody/mitotic toxin
MMAE drug conjugate), objective responses were ob-
served in 5 out of 44 patients diagnosed with advanced/
recurrent platinum-resistant ovarian cancer [30]. All five
patients who responded to the conjugate had high
expression levels of MUC16 which underscores the im-
portance of targeting strategies in increasing the ef-
fectiveness of cancer drugs by way of facilitating their
efficient delivery to the tumor cells. Instead of targeting
TR3 to MUC16 via an antibody-based strategy, we
generated Meso-TR3, in which the mature form of hu-
man mesothelin was placed at the N-terminus of human
TR3. Meso-TR3 bound avidly to endogenous MUC16,
identical to soluble mesothelin itself and triggered a ro-
bust death pathway that involved the same signaling
pathways as conventional TRAIL does (blocked by
soluble DR5-Fc and global caspase inhibition with
Z-VAD-FMK). These results have important implica-
tions because they confirm that the mesothelin targeting
Figure 5 Meso-TR3 preferentially kills MUC16-expressing tumor cells. A, HeLa cells were grown on 4-chamber slides and incubated the
following day with Meso-TR3 complexed with DR5-Fc. After washing, the cells were stained with a mixture of MUC16 pAb (red) and FLAG mAb
(green), respectively. The cells were counterstained with TOPRO3 (blue, nuclei) and analyzed by confocal microscopy. The individual channels
were overlaid to document co-localization of tumor marker and the targeted cancer drug (Merge). Original magnification: 63×. B, HeLa cells were
treated with TR3 and Meso-TR3 for 24 h. Two days post-treatment, the cells were assessed for changes in the MUC16 ratio using flow cytometry.
Representative density plots are shown from experiments done at least twice in duplicates.
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moiety is not masked by TR3 as it is still accessible to
interact with membrane-associated MUC16 in vitro. Of
note, the target recognition property of Meso-TR3 was
retained in a metastatic xenograft mouse model of
ovarian cancer under physiologic conditions in vivo.
Our results indicate that addition of mesothelin to the
TR3 domain as in Meso-TR3, increases the effectiveness
of TR3 in MUC16-positive malignancies such as ovarian
and cervical cancers (shown for OVCAR3 and HeLa cell
lines), while limiting its bioactivity on MUC16-negative
Jurkat cells. These findings have important clinical im-
plications with regard to maximizing the on-target effect
of TRAIL while keeping its off-target effects to a mini-
mum. The enhanced bioactivity of Meso-TR3 likely re-
sults from the enrichment of the cancer drug at the
tumor cell membrane. This mesothelin/MUC16 ligand/
receptor interaction serves to anchor soluble TRAIL to
the surface of MUC16-positive cancer cells, thus con-
verting the soluble drug into a membrane bound form
of TR3. This conversion has been proposed to lead to a
more efficient receptor clustering (particularly important
for DR5-induced apoptosis), which provides a more po-
tent death signal resulting in enhanced apoptosis com-
pared to its soluble counterpart [31]. The importance of
TRAIL receptor clustering in cell death is further exem-
plified by an enhanced induction of apoptosis noted in
our experimental system upon adding mesothelin anti-
body to dimerize Meso-TR3 in solution, a concept that
has just recently being explored to treat highly vas-
cularized cancers [32]. Another important aspect of the
mesothelin/MUC16 interaction is its contribution to
both homotypic (tumor cell-tumor cell) and heterotypic
(tumor cell-mesothelial cell) cell interactions [33]. The
latter type of interaction is believed to promote ad-
herence of tumor cells to the peritoneum, resulting in
metastatic spread of the primary lesion into the ab-
domen [13,34,35]. These considerations suggest that by
virtue of binding to MUC16, Meso-TR3 may also sa-
turate and therefore reduce/eliminate the available bin-
ding sites on MUC16 for adhesive interactions with
mesothelin-expressing normal endothelium, thus limiting
the peritoneal dissemination of tumor cells in addition to
augmenting TRAIL-mediated target cell death [36].
Based on semi-quantitative Western blot analyses, an ≈ 6
to 8-fold higher concentration of Meso-TR3 was required
to achieve the same biological effect as untargeted TR3 on
MUC16-deficient Jurkat cells. This finding was unexpected
since we reported earlier that we had not observed detri-
mental effects on the killing activity of a variety of domain
additions engineered onto the TR3 drug platform [12]. A
possible explanation for this finding is that in its native
state, the steric relationship between mesothelin and TR3
in the context of the Meso-TR3 fusion protein might par-
tially mask the DR/TR3 interaction leading to a reduced
killing activity on MUC16-deficient cells (Figure 6, left
panel). Only when the mesothelin targeting moiety binds
to MUC16, full exposure of the TR3 trimer is enabled and
results in an unrestricted accessibility with the surface-
associated death receptor(s) DR4/5. We therefore propose
that these structural changes, in combination with a now
membrane tethered TR3 are responsible for Meso-TR3 to
acquire its full cytotoxic potential at the target cell mem-
brane (Figure 6, right panel).
Conclusions
We have described the characterization of a downstream
modification of the novel TRAIL-based drug platform
TR3 which has many highly desirable anticancer proper-
ties. Soluble Meso-TR3 targets the cancer biomarker
MUC16 in vitro and in vivo and exhibits all the positive
features of a traditional TRAIL-based cancer drug, as well
as enhanced stability, enhanced killing capacity and fa-
vorable 1:3 stoichiometry of targeting (mesothelin) and ef-
fector domain (TR3). Since TR3 and its targeted variants
engage the same mechanistic pathways that have been ex-
plored for nearly 20 years with rTRAIL, we expect that
Meso-TR3 activity could be further enhanced in combi-
nation with chemo and/or radiation therapy [37-39]. Im-
portantly, the prodrug feature of Meso-TR3 should make
it less toxic to normal cells while enhancing the effects on
its cancer targets. We are currently in the process of
expanding our preclinical xenograft models to primary,
MUC16-expressing human malignancies including ova-
rian and pancreatic cancers. If efficacy and reduced tox-
icity in combination with chemotherapy can be confirmed




Figure 6 Proposed mechanism of Meso-TR3’s pro-drug properties.
The mesothelin moiety of Meso-TR3 partially interferes with an
unrestricted interaction of the TR3 domain and its death receptors
(left panel). In the presence of MUC16 on the cancer cell surface, the
mesothelin targeting domain is removed from the TR3 surface thus
enabling unrestricted access to and full activation of the death
receptor-mediated extrinsic death pathway (right panel).
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Additional files
Additional file 1: Figure S1. Drug quantification via Western blot
analysis. TR3 and Meso-TR3 preparations exerting identical killing
profiles on MUC16-deficient tumor cells (compare Figure 3A) were
subjected to semi-quantitative Western blot analysis under reducing
conditions using anti-TRAIL pAb. The immunoreactive bands were
quantified using QuantityOne software on a BioRad imaging system,
with Meso-TR3 approximately 6 to 8-fold more abundant than TR3.
Additional file 2: Figure S2. Meso-TR3 enhances tumor cell killing on
MUC16-positive ovarian cancer cells. Based on the ≈ 6 to 8-fold lower TR3
signal intensity on Western blot analysis (Additional file 1: Figure S1), the
TR3 concentration was increased 6-fold to match that of Meso-TR3.
A, The cell killing profiles of TR3 and Meso-TR3 were established on the
MUC16-deficient T cell leukemia cell line Jurkat. B, The same conditions
were applied to the MUC16-positive cell line OVCAR3. Statistical analysis
was calculated using the Student’s t-test (mean ± SEM).
Additional file 3: Figure S3. Meso-TR3 has increased bioactivity on
MUC16-positive cervical cancer cells. A, The cell killing profiles of TR3 and
Meso-TR3 were established on the MUC16-deficient T cell leukemia cell
line Jurkat as described in Figure 3A, with an ≈ 6 to 8-fold lower TR3
signal intensity on Western blot analysis (Additional file 1: Figure S1).
B, The same conditions were then applied to the MUC16-positive cervical
cancer cell line HeLa. Due to a more rapid cell death induction of Meso-TR3
in this cell line, the killing assay for both cell lines was initiated 6 h post-
treatment. Statistical analysis was calculated using the Student’s t-test
(mean ± SEM).
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